Article 2
Amendments to Regulation (EC) No 1394/2007
Article 20(3) of Regulation (EC) No 1394/2007 is replaced by the following:
‘3.   The Executive Director of the Agency shall ensure appropriate coordination between the Committee for Advanced Therapies and the other Committees of the Agency, in particular the Committee for Medicinal Products for Human Use, the Pharmacovigilance Risk Assessment Committee and the Committee for Orphan Medicinal Products, their working parties and any other scientific advisory groups.’.
